FDA approval and regulation of medical devices: a primer

This article gives an overview of medical device classification in the U.S. and of the regulations governing the FDA’s review of application to market medical devices.

Read more >

When competitive intelligence is predictive rather than reactive, biopharma companies can grab the edge

In the dynamic global biopharma landscape, competitive intelligence (CI) is as indispensable as ever.

Read more >

Cortellis M&A Landscape: Notable mergers & acquisitions of Q1 2017

The mergers and acquisitions (M&A) activity in the Life Sciences sector in the first quarter of 2017 continued to progress like previous periods. In the first months of the year, 126 active M&A deals were reported by Clarivate Cortellis Deals Intelligence with a total disclosed value of $76 billion.

Read more >

Positive outlook for CDMOs at CPhI North America, but companies need to be ready for challenges

CPhI North America, running concurrently with InformEx, is a new addition to the global series of CPhI events.

Read more >

DCAT Week ’17 session looks at emerging pharma market trends

The health of emerging pharmaceutical companies can be assessed, in part, by financing and partnership activity with larger companies, Richard Harrison, Chief Scientific Officer at Clarivate Analytics, told a DCAT Week ’17 audience in a session titled “Emerging Pharma: Market Overview, Project Management and CMC Readiness.”

Read more >